Drug Safety, Transparency Are FDA Priorities in Five-Year Plan

The FDA plans to continue its recent focus on drug safety and transparency over the next five years, with postmarket surveillance and science-based decision making also identified as important areas for the agency. Under the five-year plan for 2011–2015, the FDA looks to carry on several of the initiatives put in place since Margaret Hamburg took over as commissioner last year.
Washington Drug Letter